The problem for me is, I can't imagine what incentive there is...

The problem for me is, I can't imagine what incentive there is for the price to go up.

At this stage the market values NEU at $1.40-$1.50. What could cause the price to go up?

RETT: I can't think of any price driver until after the Ph III trial. I can't imagine ther'd be any price appreciation just because the trial starts and patients are being enrolled.

FXS: If there had been a comcrete plan for this it would have been in the ann, I believe. Will this has the potential to pleasantly surprise it's still unlikely for this to generate a price rise because.... the deal's already done.

TROF IN GENERAL: while there might be an upside due to deals for ROW, is anyone going to do anything before the Ph III trial is in? Given the benchmark set by Acadia, why would ROW pay significantly more?

2591: is preclinical and at least 5 years away from having Ph II results, and I don't believe NEU can pay for a Ph II trial because they don't have the money. This is why the upfront mattered.

I believe the Rett Ph III trial will take at least a year, maybe 18 months. Let's say results come through end 2020. What serious, company making announcement can they make in the next 2 and a half years? I'm open to suggestions.